Literature DB >> 21209235

Ethnic differences in pharmacokinetics in new drug applications and approved doses in Japan.

Satoshi Fukunaga1, Makiko Kusama, Frank L Arnold, Shunsuke Ono.   

Abstract

Mesh：

Substances：

Year:  2011        PMID： 21209235     DOI： 10.1177/0091270010381500

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN： 0091-2700            Impact factor:   3.126


× No keyword cloud information.
  10 in total

1.  Lack of ethnic differences of moxifloxacin and metabolite pharmacokinetics in East Asian men.

Authors:  M Kaneko; T Aoyama; Y Ishida; A Miyamoto; Y Saito; M Tohkin; S Kawai; Y Matsumoto
Journal:  J Pharmacokinet Pharmacodyn       Date:  2017-11-23       Impact factor: 2.745

2.  Differences in maximum tolerated doses and approval doses of molecularly targeted oncology drug between Japan and Western countries.

Authors:  Hideki Maeda; Tatsuo Kurokawa
Journal:  Invest New Drugs       Date:  2014-03-11       Impact factor: 3.850

3.  Physiologically based pharmacokinetic (PBPK) modelling of tamsulosin related to CYP2D6*10 allele.

Authors:  Pureum Kang; Hye-Jung Park; Chang-Keun Cho; Yun Jeong Lee; Jung-Woo Bae; Choon-Gon Jang; Seok-Yong Lee
Journal:  Arch Pharm Res       Date:  2021-11-09       Impact factor: 4.946

4.  Pharmacokinetics and pharmacodynamics of single-dose oral tolvaptan in fasted and non-fasted states in healthy Caucasian and Japanese male subjects.

Authors:  Susan E Shoaf; Seong Ryul Kim; Patricia Bricmont; Suresh Mallikaarjun
Journal:  Eur J Clin Pharmacol       Date:  2012-05-15       Impact factor: 2.953

5.  Safety, tolerability, pharmacokinetics and pharmacodynamics of belimumab in Japanese patients with mild-to-moderate systemic lupus erythematosus.

Authors:  Masanori Yamada; Mikio Akita; Tomofumi Nakagawa; Naoki Takahashi; Akira Endo; Pascal Yoshida
Journal:  J Drug Assess       Date:  2013-04-12

6.  Ataluren Pharmacokinetics in Healthy Japanese and Caucasian Subjects.

Authors:  Ronald Kong; Oscar L Laskin; Diksha Kaushik; Fengbin Jin; Jiyuan Ma; Joseph McIntosh; Marcio Souza; Neil Almstead
Journal:  Clin Pharmacol Drug Dev       Date:  2019-01-10

7.  Enhanced Extraction Technique of Omarigliptin from Human Plasma-Applied to Biological Samples from Healthy Human Volunteers.

Authors:  Shereen Mowaka; Nermeen Ashoush; Mariam Tadros; Noha El Zahar; Bassam Ayoub
Journal:  Molecules       Date:  2020-09-15       Impact factor: 4.411

8.  Absence of ethnic differences in the pharmacokinetics of moxifloxacin, simvastatin, and meloxicam among three East Asian populations and Caucasians.

Authors:  Tomoko Hasunuma; Masahiro Tohkin; Nahoko Kaniwa; In-Jin Jang; Cui Yimin; Masaru Kaneko; Yoshiro Saito; Masahiro Takeuchi; Hiroshi Watanabe; Yasushi Yamazoe; Yoshiaki Uyama; Shinichi Kawai
Journal:  Br J Clin Pharmacol       Date:  2016-03-14       Impact factor: 4.335

9.  Pharmacokinetics and Pharmacodynamics of Meloxicam in East Asian Populations: The Role of Ethnicity on Drug Response.

Authors:  Takahiko Aoyama; Yoshimasa Ishida; Masato Kaneko; Aoi Miyamoto; Yoshiro Saito; Masahiro Tohkin; Shinichi Kawai; Yoshiaki Matsumoto
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2017-11-23

10.  A phase 1 study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of TAK-063, a selective PDE10A inhibitor.

Authors:  Max Tsai; Lambros Chrones; Jinhui Xie; Hakop Gevorkyan; Thomas A Macek
Journal:  Psychopharmacology (Berl)       Date:  2016-08-30       Impact factor: 4.530
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.